Yahoo Finance

Annovis Bio (ANVS) announced that the first two patients have been entered into the Phase 3 study evaluating buntanetap in early AD. “The launch of our highly anticipated AD study is a significant milestone in advancing buntanetap toward market approval and addressing the unmet medical need of millions of patients. Our previous trials have delivered compelling results, and we have meticulously designed a comprehensive protocol to evaluate both the symptomatic and potential disease-modifying effects of our drug candidate,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis.

Maximize Your Portfolio with Data Driven Insights:

• Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.

• Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on ANVS:

• Annovis Bio falls -25.6%

• Annovis Bio announces pricing of $21M offering of stock, warrants

• Annovis Bio granted U.S. patent covering buntanetap

• Annovis Bio announces FDA acceptance of protocol for Phase 3 AD study

• Annovis Bio Advances Alzheimer’s and Parkinson’s Drug Trials